Abbott Laboratories (NYSE:ABT) Shares Sold by Eads & Heald Wealth Management

Eads & Heald Wealth Management trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,944 shares of the healthcare product maker’s stock after selling 93 shares during the quarter. Eads & Heald Wealth Management’s holdings in Abbott Laboratories were worth $1,577,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. 1832 Asset Management L.P. boosted its holdings in Abbott Laboratories by 115.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 161,505 shares of the healthcare product maker’s stock worth $16,782,000 after buying an additional 86,707 shares during the last quarter. Epoch Investment Partners Inc. lifted its position in shares of Abbott Laboratories by 1.7% in the second quarter. Epoch Investment Partners Inc. now owns 60,703 shares of the healthcare product maker’s stock valued at $6,308,000 after acquiring an additional 988 shares in the last quarter. Certified Advisory Corp acquired a new stake in shares of Abbott Laboratories in the second quarter worth approximately $622,000. Resources Management Corp CT ADV raised its stake in Abbott Laboratories by 0.9% in the 2nd quarter. Resources Management Corp CT ADV now owns 60,727 shares of the healthcare product maker’s stock valued at $6,310,000 after purchasing an additional 522 shares during the last quarter. Finally, Providence Capital Advisors LLC lifted its holdings in Abbott Laboratories by 0.8% in the 2nd quarter. Providence Capital Advisors LLC now owns 61,846 shares of the healthcare product maker’s stock valued at $6,426,000 after purchasing an additional 474 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 2.9 %

ABT stock opened at $116.78 on Wednesday. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $121.64. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The company has a market cap of $202.55 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 2.43 and a beta of 0.73. The company has a fifty day moving average price of $114.87 and a 200 day moving average price of $112.95.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.02%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s dividend payout ratio (DPR) is currently 71.73%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ABT. Royal Bank of Canada reissued an “outperform” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday. Oppenheimer started coverage on shares of Abbott Laboratories in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 target price on the stock. UBS Group upped their price target on Abbott Laboratories from $143.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Piper Sandler lifted their price objective on Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, October 17th. Finally, Barclays raised their target price on Abbott Laboratories from $143.00 to $149.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $131.93.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.